Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNYSE:CATXNASDAQ:CTSONASDAQ:SKIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsWay$10.73+2.9%$9.17$5.25▼$11.79$202.50M1.2570,032 shs14,400 shsCATXPerspective Therapeutics$2.39-4.8%$2.24$1.60▼$16.70$177.41M1.111.04 million shs656,911 shsCTSOCytosorbents$0.85-0.5%$0.97$0.70▼$1.61$52.91M1.17146,059 shs52,325 shsSKINBeauty Health$1.61-6.9%$1.24$0.78▼$2.59$201.64M0.881.05 million shs361,625 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsWay+2.88%+8.27%+22.07%-0.19%+96.16%CATXPerspective Therapeutics-4.78%-9.13%+3.46%-14.18%-83.96%CTSOCytosorbents-0.47%-6.11%-21.03%-26.52%-10.11%SKINBeauty Health-6.94%-7.47%+70.19%0.00%-39.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsWay3.5829 of 5 stars3.55.00.00.03.20.81.9CATXPerspective Therapeutics3.2234 of 5 stars4.60.00.00.02.02.50.6CTSOCytosorbents2.026 of 5 stars3.53.00.00.02.50.00.6SKINBeauty Health0.3731 of 5 stars0.80.00.00.02.83.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsWay 3.00Buy$14.2532.81% UpsideCATXPerspective Therapeutics 3.18Buy$12.50423.01% UpsideCTSOCytosorbents 3.00Buy$5.50550.89% UpsideSKINBeauty Health 1.67Reduce$1.42-12.01% DownsideCurrent Analyst Ratings BreakdownLatest CTSO, SKIN, CATX, and BWAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/5/2025SKINBeauty HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.255/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/7/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $10.004/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/31/2025CATXPerspective TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/27/2025CATXPerspective TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $15.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsWay$43.46M4.66N/AN/A$2.50 per share4.29CATXPerspective Therapeutics$1.43M124.06N/AN/A$2.67 per share0.90CTSOCytosorbents$35.33M1.50N/AN/A$0.52 per share1.63SKINBeauty Health$322.47M0.63N/AN/A$0.48 per share3.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsWay-$4.20M$0.20107.3167.06N/A3.88%3.52%2.26%8/5/2025 (Estimated)CATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/11/2025 (Estimated)CTSOCytosorbents-$28.51M-$0.28N/AN/AN/A-49.47%-118.54%-42.31%8/12/2025 (Estimated)SKINBeauty Health-$100.12M-$0.41N/AN/AN/A-8.11%-44.83%-3.54%N/ALatest CTSO, SKIN, CATX, and BWAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/13/2025Q1 2025BWAYBrainsWay$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/8/2025Q1 2025SKINBeauty Health-$0.13-$0.08+$0.05-$0.08$63.88 million$69.60 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/12/2025Q4 2024SKINBeauty Health-$0.10-$0.08+$0.02-$0.08$78.02 million$83.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainsWayN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainsWayN/A4.524.23CATXPerspective TherapeuticsN/A9.609.60CTSOCytosorbents1.061.971.58SKINBeauty Health9.236.565.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsWay30.11%CATXPerspective Therapeutics54.66%CTSOCytosorbents32.87%SKINBeauty Health93.26%Insider OwnershipCompanyInsider OwnershipBWAYBrainsWay19.00%CATXPerspective Therapeutics3.72%CTSOCytosorbents7.30%SKINBeauty Health41.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsWay12018.87 million15.24 millionNot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableCTSOCytosorbents22062.61 million51.07 millionOptionableSKINBeauty Health1,030125.25 million73.23 millionOptionableCTSO, SKIN, CATX, and BWAY HeadlinesRecent News About These CompaniesWhy Hydration Is the Secret to Younger Looking SkinMay 24 at 1:50 AM | latimes.comSkin & Soul Beauty helps clients glow from inside outMay 23 at 8:50 PM | krqe.comDiscover the hidden powers of pomegranates for beauty & healthMay 23 at 8:50 PM | msn.comYou Are Doing Too Much for Your Skin BarrierMay 23 at 10:46 AM | msn.comSurprise! These 13 Sunscreens Are Also Excellent Skin CareMay 23 at 10:46 AM | msn.com‘Your skin impacts your psychology’: Paul Brunson on the relationship between skincare and wellbeingMay 23 at 5:45 AM | msn.com5 Benefits Of Mango Seeds For Skin, Hair, Weight Loss And MoreMay 23 at 5:45 AM | food.ndtv.comNautapa Skin Care: Nautapa is about to start, take special care of your skin or else you will face big trouble..May 22 at 5:48 AM | msn.com16 of the best sunscreens for sensitive skin, according to dermatologistsMay 22 at 12:47 AM | cnn.comNew Project Aims to Document Worldwide Skin Care CrisisMay 21 at 6:56 PM | medscape.com2015 vs 2025 Skincare: A skin doctor reveals what’s in and what’s outMay 21 at 6:56 PM | indiatvnews.comBizarre, new beauty trend turns your skin orange — and could land you in the ER, experts warnMay 21 at 6:56 PM | msn.comBeauty Routines from Around the World: Global Secrets to Glowing SkinMay 21 at 6:56 PM | msn.comRadiant risks: the dark side of skin bleaching and tanning for beautyMay 21 at 2:35 AM | msn.comWhat Dermatologists Have to Say About Using Beef Tallow for Your SkinMay 20, 2025 | msn.comMeet the winners of the 2025 Women’s Health Skincare AwardsMay 20, 2025 | womenshealthmag.comMeet the winners of the 2025 Women’s Health Skincare AwardsMay 20, 2025 | womenshealthmag.comI Use This K-Beauty Skin Care Hack Every Night. Here's Why You Should, TooMay 20, 2025 | msn.comWant skin care that really multitasks? It's time to try a rice serumMay 20, 2025 | msn.comSusquehanna Portfolio Strategies LLC Cuts Stock Position in The Beauty Health Company (NASDAQ:SKIN)May 20, 2025 | marketbeat.comSkin Care Tips: Keep your face fresh in summer, know easy skin care tips..May 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Is Energy Transfer Undervalued or a Value Trap?By Chris Markoch | May 8, 2025View Is Energy Transfer Undervalued or a Value Trap?CTSO, SKIN, CATX, and BWAY Company DescriptionsBrainsWay NASDAQ:BWAY$10.73 +0.30 (+2.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.38 -0.36 (-3.31%) As of 05/23/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Perspective Therapeutics NYSE:CATX$2.39 -0.12 (-4.78%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.44 +0.05 (+2.30%) As of 05/23/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Cytosorbents NASDAQ:CTSO$0.84 0.00 (-0.47%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+1.30%) As of 05/23/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Beauty Health NASDAQ:SKIN$1.61 -0.12 (-6.94%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.66 +0.05 (+3.42%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
